With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
The 2014 Ebola outbreak demonstrated that deadly diseases do not respect international borders, and that the world is underprepared for the next such incident. In addition, the global spread of infections resistant to almost all known antibiotics underlines that safeguarding human health is a joint endeavor. Several governments have signed up to the Global Health Security Agenda to ensure better cooperation and preparedness. CGD assesses progress and obstacles and suggests how international agencies can ensure the world is ready to fight dangerous and widespread infections when, not if, they next emerge.
Since Charles, Janeen, and I last wrote about the links between drug-resistant superbugs and antibiotic use in livestock, there has been a slew of new interesting, terrifying, and informative things to read on the topic. And they all underscore the need for a global approach to reduce agricultural use of antibiotics to promote animal growth and prevent disease in large, concentrated feeding operations. We offered initial ideas on the essential elements of a global treaty here. You can also read more about the problem, and the steps taken thus far to address it, in my new CGD book, Global Agriculture and the American Farmer: Opportunities for US Leadership.
McDonald's has just gone global with its commitment to serve chicken free from antibiotics that are critically important to human health. Building on a similar phase-out in its US chicken supply in 2016, the company will ban critical antibiotic use from sourced chicken in a handful of high-income countries and Brazil in 2018, expanding to a longer list of “designated markets” by 2027. That's evidence of both the potential to reduce global antibiotic use in livestock and the vital role consumers can play in speeding progress.
The 2014-2015 Ebola outbreak in West Africa was a disturbing demonstration of the inadequacy of international institutions to assist the affected peoples or learn how to better treat and prevent their illness. Experts on a CGD panel discussed their experiences working on crisis response during the Ebola outbreak—and how we can do better.
The 2014-2015 Ebola epidemic broke out and affected thousands of people at a time when there were no medicines approved to treat or prevent Ebola. Poor infrastructure, capacity gaps, widespread mistrust, and disagreements over the design and ethical nature of any clinical trials complicated efforts to conduct research on investigational drugs and vaccines. In the wake of the outbreak, the National Academies of Sciences, Engineering, and Medicine tasked a committee with analyzing the clinical trials carried out during the outbreak and developing recommendations to improve the implementation of such trials in the future. In this session, committee members Gerald Keusch and David Peters will discuss findings from the committee’s recently released report and the kind of governance structures that need to be in place for effective international coordination and collaboration.